| Korean startups with standout AI capabilities are attracting major investment across the local VC market
| Government ramps up support as AI becomes a national growth engine
| AI-driven challengers reshape healthcare, finance, and legal sectors with specialized technologies
| Emerging “next unicorns” like JNPMEDI, BHSN, and SelectStar gain momentum as category-defining innovators
Korea’s startup investment landscape is shifting rapidly toward companies with differentiated AI technologies, drawing significant capital and confirming AI as the core driver of future industrial growth. Investors are increasingly prioritizing startups that position AI not as an add-on but as the foundation of their business model and long-term competitiveness.
The Korean government has also declared the present moment the “final golden window” to secure leadership in the age of AI transformation, rolling out aggressive support programs across research, infrastructure, and regulatory environments. As national attention intensifies, a new cohort of AI-powered K-startups is emerging as key players to watch.
JNPMEDI Joins Forces With NAVER to Accelerate AI-Driven Innovation in Clinical Trials
Among the most notable is JNPMEDI, a digital platform–based consultancy specializing in new drug and innovative medical device development. The company recently secured strategic investment from NAVER’s D2 Startup Factory and venture firm TBT, drawing strong interest from the healthcare and AI sectors.
JNPMEDI is widely recognized for leading the digital transformation of clinical trials in Korea. Its core strength lies in combining a decade of clinical operations expertise with AI-driven technology. The company’s proprietary platform, Maven Clinical Cloud, integrates AI at every stage of the clinical trial lifecycle—from optimizing protocol design to detecting and correcting data-entry errors in real time. This automation significantly improves data accuracy and operational efficiency while helping CROs reduce human error and streamline trial execution.
With the new investment from NAVER and TBT, JNPMEDI plans to accelerate the advancement of its AI-enabled infrastructure and expand the scope of its platform. NAVER’s AI capabilities are expected to enhance Maven Clinical Cloud’s performance further and strengthen its position as a next-generation digital clinical solution.
Both companies also plan to collaborate on discovering and investing in promising digital healthcare startups, as well as supporting their global expansion—laying the groundwork for a broader digital transformation across the healthcare ecosystem.
| Korean startups with standout AI capabilities are attracting major investment across the local VC market
| Government ramps up support as AI becomes a national growth engine
| AI-driven challengers reshape healthcare, finance, and legal sectors with specialized technologies
| Emerging “next unicorns” like JNPMEDI, BHSN, and SelectStar gain momentum as category-defining innovators
Korea’s startup investment landscape is shifting rapidly toward companies with differentiated AI technologies, drawing significant capital and confirming AI as the core driver of future industrial growth. Investors are increasingly prioritizing startups that position AI not as an add-on but as the foundation of their business model and long-term competitiveness.
The Korean government has also declared the present moment the “final golden window” to secure leadership in the age of AI transformation, rolling out aggressive support programs across research, infrastructure, and regulatory environments. As national attention intensifies, a new cohort of AI-powered K-startups is emerging as key players to watch.
JNPMEDI Joins Forces With NAVER to Accelerate AI-Driven Innovation in Clinical Trials
Among the most notable is JNPMEDI, a digital platform–based consultancy specializing in new drug and innovative medical device development. The company recently secured strategic investment from NAVER’s D2 Startup Factory and venture firm TBT, drawing strong interest from the healthcare and AI sectors.
JNPMEDI is widely recognized for leading the digital transformation of clinical trials in Korea. Its core strength lies in combining a decade of clinical operations expertise with AI-driven technology. The company’s proprietary platform, Maven Clinical Cloud, integrates AI at every stage of the clinical trial lifecycle—from optimizing protocol design to detecting and correcting data-entry errors in real time. This automation significantly improves data accuracy and operational efficiency while helping CROs reduce human error and streamline trial execution.
With the new investment from NAVER and TBT, JNPMEDI plans to accelerate the advancement of its AI-enabled infrastructure and expand the scope of its platform. NAVER’s AI capabilities are expected to enhance Maven Clinical Cloud’s performance further and strengthen its position as a next-generation digital clinical solution.
Both companies also plan to collaborate on discovering and investing in promising digital healthcare startups, as well as supporting their global expansion—laying the groundwork for a broader digital transformation across the healthcare ecosystem.